Kenvue Jumps 2.55% on Strong Q4 Earnings Beat

Kenvue stock rose 2.55% to close at $18.88 after reporting better-than-expected fourth quarter results. The consumer health products company, which owns brands like Tylenol and Neutrogena, posted adjusted earnings of $0.27 per share, beating analyst estimates of $0.22.

Revenue reached $3.78 billion, representing 3.2% year-over-year growth. The positive earnings surprise drove above-average trading volume of 46.9 million shares, about 3.9% higher than the three-month average.

Several analysts responded to the strong results by raising their price targets for Kenvue stock into the $18-$20 range. This positive momentum comes despite the stock being down approximately 30% since its 2023 IPO.

The company also provided updates on its pending acquisition by Kimberly-Clark, a $48.7 billion cash-and-stock deal announced in November. Kenvue announced a worldwide restructuring plan tied to the merger that includes reducing its workforce by 3.5%.

For a stock that has struggled since going public, beating earnings expectations provides much-needed validation of Kenvue's business model. The 2.55% gain on above-average volume suggests institutional investors are taking notice of the improved fundamentals.

The analyst price target increases to $18-$20 range indicate professional confidence in Kenvue's near-term prospects. This is particularly important given the stock's post-IPO decline and could signal the beginning of a recovery phase.

The Kimberly-Clark acquisition, while still 2+ years from closing, provides a potential floor for the stock price. However, the $250 million in restructuring charges planned for 2026 remind investors that merger integration costs lie ahead.

Kenvue's performance also offers insights into the broader consumer health sector. While peers showed mixed results, Kenvue's ability to grow revenue in a challenging environment suggests resilience in essential healthcare products.